Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercus ilex pollen allergen extract
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Percutaneous, Intradermal, Subcutaneous
01
Overview
Quercus ilex pollen allergen extract is a biological allergen extract developed by Inmunotek S.L. for the diagnosis and treatment of oak pollen allergies. Derived from the pollen of the holm oak (*Quercus ilex*), the extract contains allergenic proteins that interact with specific IgE antibodies in sensitized individuals. It is primarily used in in vivo diagnostic procedures, such as skin prick testing, to identify patients with allergic rhinitis, rhinoconjunctivitis, or asthma triggered by oak pollen. Additionally, it is investigated for use in allergen-specific immunotherapy (allergy vaccines) to induce immune tolerance. Clinical studies, including Phase 2 trials, have focused on determining the allergenic potency of the extract by comparing skin prick test wheal sizes to histamine-induced responses.
- Brand names
- ALXOIDOralTek
- Other names
- holm oak pollen allergen extract
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Quercus ilex pollen allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quercus ilex pollen allergen extract.